» Articles » PMID: 17943970

Somatic KIT Mutations Occur Predominantly in Seminoma Germ Cell Tumors and Are Not Predictive of Bilateral Disease: Report of 220 Tumors and Review of Literature

Overview
Date 2007 Oct 19
PMID 17943970
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in the KIT gene occur in approximately 8% of all testicular germ cell tumors (TGCT) and KIT is the most frequently mutated known cancer gene. One report has shown that 93% of patients with bilateral disease have a mutation at codon 816 of the KIT gene. Importantly, this suggests that the identification of a mutation in KIT is predictive of the development of a contralateral TGCT. We investigated the frequency and type of mutations in KIT in a series of 220 tumors from 211 patients with TGCTs and extragonadal germ cell tumors. In 170 patients with unilateral TGCT and no additional germ cell tumour, we identified one exon 11 mutation in a patient with unilateral TGCT and eight activating KIT mutations in exon 17 (9/175, 5.1%). In 32 patients with bilateral TGCT, one patient had an activating KIT mutation in exon 17 (3.1%). The incidence of activating KIT mutations in sporadic TGCT vs. familial TGCT was not significantly different. All mutations were identified in seminomas. Three extragonadal primary germ cell tumors were examined and in one tumor an activating KIT mutation was demonstrated in the pineal germinoma. Interestingly, this mutation was also seen in the patient's testicular seminoma. We find no evidence for an increased frequency of KIT mutations in bilateral TGCT.

Citing Articles

Driver mutations associated with signatures of platinum sensitivity in germ cell tumors.

Sawa Y, Jia L, Krause H, Meagher M, Millard F, Elliott A NPJ Precis Oncol. 2024; 8(1):249.

PMID: 39488665 PMC: 11531533. DOI: 10.1038/s41698-024-00727-2.


miR-21, miR-29a, and miR-106b: serum and tissue biomarkers with diagnostic potential in metastatic testicular cancer.

Ujfaludi Z, Fazekas F, Biro K, Olah-Nemeth O, Buzogany I, Sukosd F Sci Rep. 2024; 14(1):20151.

PMID: 39215008 PMC: 11364861. DOI: 10.1038/s41598-024-70552-x.


What Have We Learned from Molecularly Informed Clinical Trials on Thymomas and Thymic Carcinomas-Current Status and Future Directions?.

Maniar R, Loehrer Sr P Cancers (Basel). 2024; 16(2).

PMID: 38254905 PMC: 10813974. DOI: 10.3390/cancers16020416.


c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights.

Abdellateif M, Bayoumi A, Mohammed M Onco Targets Ther. 2023; 16:785-799.

PMID: 37790582 PMC: 10544070. DOI: 10.2147/OTT.S404648.


Integrated genomic analysis reveals aberrations in WNT signaling in germ cell tumors of childhood and adolescence.

Xu L, Pierce J, Sanchez A, Chen K, Shukla A, Fustino N Nat Commun. 2023; 14(1):2636.

PMID: 37149691 PMC: 10164134. DOI: 10.1038/s41467-023-38378-9.